PRINCETON, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the American Association for the Study of Liver Diseases (AASLD) on Sunday, November 2, 2008 starting at 5:30 PM PT. During this webcast, management will review Pharmasset's progress on the programs that are the subject of poster presentations at AASLD.
To access a simultaneous webcast of this event via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.
Abstracts are available on the AASLD website (AASLD.org).
"Antiviral Activity Of The HCV Nucleoside Polymerase Inhibitor R7128 In HCV Genotype 2 And 3 Prior Non-Responders: Interim Results Of R7128 1500mg BID With PEG-IFN And Ribavirin For 28 Days" will be presented in a poster session on Monday November 3rd at 8am PT. Authors of the study are E. J. Gane; M. Rodriguez-Torres; D. R. Nelson; I. M. Jacobson; J. G. McHutchison; L. Jeffers; A. Beard; S. Walker; N. Shulman; W. Symonds; E. Albanis; M. M. Berrey. Abstract: LB10
"Potent Antiviral Response To The HCV Nucleoside Polymerase Inhibitor R7128 For 28 Days With Peg-Ifn And Ribavirin: Subanalysis by Race/Ethnicity, Weight and HCV Genotype" will be presented in a poster session on Tuesday November 4th at 8am PT. Authors of the study are M. Rodriguez-Torres; J. Lalezari; E. J. Gane; E. DeJesus; D. R. Nelson; G. T. Everson; I. M. Jacobson; K. Reddy; J. G. McHutchison; A. Beard; S. Walker; W. Symonds; M. M. Berrey. Abstract: 1899
"Combination of the NS3/4A Protease Inhibitor ITMN-191 (R7227) with the Active Moiety of the NS5B Inhibitors R1626 or R7128 Enhances Replicon Clearance and Reduces the Emergence of Drug Resistant Variants" will be presented in a poster session on Tuesday November 4th at 8am PT. Authors of the study are H. Tan; S. Rajyaguru; T. Wu; M. McCown; S. Ali; W. Jiang; M. J. Otto; P. A. Furman; I. Najera; K. Klumpp; J. Symons; N. Cammack; L. M. Blatt; S. Seiwert. Abstract: 1885.
"PSI-7851: A Novel Liver-Targeting Nucleotide Prodrug for the Treatment of Hepatitis C" will be presented in a poster session on Tuesday November 4th at 8am PT. Authors of the study are P. A. Furman; P. Wang; C. Niu; D. Bao; W. Symonds; D. Nagarathnam; H. Micolochick Steuer; S. Rachakonda; B. S. Ross; M. J. Otto; M. Sofia. Abstract: 1901
In addition, a number of abstracts/posters will be presented discussing clevudine.
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing three product candidates. Clevudine,
for the treatment of chronic HBV infection, is enrolling Phase 3 clinical
trials for registration in North, Central and South America and Europe.
Clevudine is already approved for HBV in South Korea and marketed by
Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128,
an oral treatment for chronic HCV infection, has completed a 4-week
clinical trial in combination with Pegasys(R) plus Copegus(R) through a
strategic collaboration with Roche. Racivir, which is being developed for
the treatment of HIV in combination with other approved HIV drugs, has
completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.
Richard E. T. Smith, Ph.D.
Vice President, Investor Relations and Corporate Communications
Office: +1 (609) 613-4181
Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.
|SOURCE Pharmasset, Inc.|
Copyright©2008 PR Newswire.
All rights reserved